| 28.185 -5.815 (-17.1%) | 05-04 12:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 38.4  |
1-year : | 42.64 |
| Resists | First : | 32.87 |
Second : | 36.5 |
| Pivot price | 0 | |||
| Supports | First : | 27 |
Second : | 22.46 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 32 | Low : | 28.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COAG ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Mon, 04 May 2026
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Sat, 02 May 2026
COAG Price Today: Hemab Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Sat, 02 May 2026
Latest Hemab Therapeutics Holdings, Inc. Common Stock Stock News & COAG Headlines - CoinCodex
Thu, 30 Apr 2026
Total common shares outstanding of Hemab Therapeutics Holdings Inc. – NASDAQ:COAG - TradingView
Thu, 30 Apr 2026
Hemab Therapeutics prices IPO at $18 per share By Investing.com - Investing.com Nigeria
Thu, 30 Apr 2026
Hemab Therapeutics prices IPO at $18 per share - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.2 % |
| Return on Equity (ttm) | -47 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -19.53 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|